Mainstay Medical Holdings Plc

Mainstay Medical Holdings Plc

Mainstay Medical Holdings Plc is a medical technology asset manager registered in Dublin, Ireland, with operational offices in Cupertino, Menlo Park, and New York. The firm's identity is built around its lead product, the ReActiv8 Active Implantable Medical Device, an implanted neurostimulation system for chronic low back pain that received FDA approval in 2020. The firm deploys capital across three asset classes: direct investment in medical device companies, acquisition and restructuring of pain management practice networks, and licensing of neurostimulation intellectual property. Confirmed portfolio includes the NeuroResource Group acquisition (2019), which expanded its provider network for implantable therapies. The geographic footprint is concentrated in the US and Ireland, with regulatory filings listing Dublin as headquarters. Total deployment is undisclosed, and the team headcount is not publicly confirmed. The firm maintains no known philanthropic foundation or adjacent vehicles beyond the parent company Mainstay Medical Holdings. In 2023, the firm announced CE Mark approval renewal for ReActiv8 in the European Union, supporting continued commercial expansion (per the firm, 2023). The structural differentiator is vertical integration: Mainstay both develops and commercialises implantable devices and directly owns the clinical practices that implant them. This clinician-controlled model — where the firm's physicians are both operators and investors — is unusual among medtech VCs, which typically focus on device funding without practice ownership.